Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.46 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.44 |
| ▸ | CDC25B | P30305 | 6/20 | 0.44 |
| ▸ | TACR2 | P21452 | 2/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8137175 | 1.00 | HTR1A (0.47) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL1170781 | 1.00 | HTR1A (0.47) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16237994 | 1.00 | HTR1A (0.47) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL14429227 | 1.00 | HTR1A (0.47) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL5515020 | 1.00 | HTR1A (0.47) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL18464593 | 1.00 | HTR1A (0.47) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL24645797 | 0.99 | HTR1A (0.48) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL21020652 | 0.99 | HTR1A (0.48) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL7027519 | 0.92 | SSTR4 (0.44) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL5941739 | 0.91 | SSTR4 (0.44) | HTR1ASSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086767-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | INSTITUT PASTEUR | 2011-04-14 | — | — | US | disclosed |
| EP-2271752-A2 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | Institut Pasteur (FR) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009112950-A2 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | INSTITUT PASTEUR (FR) | 2009-09-17 | — | — | WO | disclosed |
| EP-2100965-A1 | Mutants of glycoside hydrolases and uses thereof for synthesizing complex oligosaccharides and disaccharide intermediates | Institut Pasteur (FR) | 2009-09-16 | — | — | EP | disclosed |
| US-5864022-A | Process for the manufacture of 3-amino-substituted glycosylated bile acids | INTERCARDIA, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0766690-A4 | PROCESS FOR THE MANUFACTURE OF 3-AMINO-SUBSTITUTED GLYCOSYLATED BILE ACIDS | TRANSCELL TECHNOLOGIES INC (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5731423-A | OXIDATION | TRANSCELL TECHNOLOGIES, INC. (US) | 1998-03-24 | — | — | US | disclosed |
| US-5693770-A | Process for the manufacture of 3-amino-substituted glycosylated bile acids | TRANSCELL TECHNOLOGIES, INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0766690-A1 | PROCESS FOR THE MANUFACTURE OF 3-AMINO-SUBSTITUTED GLYCOSYLATED BILE ACIDS | TRANSCELL TECHNOLOGIES, INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996000230-A1 | PROCESS FOR THE MANUFACTURE OF 3-AMINO-SUBSTITUTED GLYCOSYLATED BILE ACIDS | TRANSCELL TECHNOLOGIES, INC. (US) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086767-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | ENGASE, GALE, MGAM | HTR1A 4643/4885SSTR1 4504/4885SSTR2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.